IMPEDE-VTE

IMPEDE‑VTE estimates the risk of venous thromboembolism in multiple myeloma patients initiating therapy.

Loading...

Immunomodulatory drug use
BMI ≥ 25 kg/m2
Pelvic, hip or femur fracture
Erythropoiesis-stimulating agent
Doxorubicin use
Dexamethasone use
Ethnicity/race is Asian/Pacific Islander
History VTE before MM
Tunneled line/central venous catheter
Existing thromboprophylaxis: therapeutic LMWH or warfarin use
Existing thromboprophylaxis: prophylactic LMWH or aspirin use

Indicações de Uso

Identifies newly diagnosed multiple myeloma patients starting IMiD‑based therapy who need VTE risk stratification. Assists in selecting primary thromboprophylaxis by categorizing patients into low, intermediate, or high risk based on validated predictors. External validation shows moderate discrimination (c‑statistic ~0.64) and superior performance to IMWG/NCCN criteria 1 [Level II evidence].

Insights e Precauções

Stratify MM patients on IMiD‑based therapy into low, intermediate, and high VTE risk, but apply cautiously because external validation shows borderline discrimination (c‑statistic ~0.64) and need for prospective validation 1 [Level II evidence]; 2 [Level II evidence]. Insights: captures MM‑specific treatment triggers; simple to score. Cautions: risk inflation with multiple time‑varying factors, limited generalizability, and not yet guideline‑endorsed as definitive.

IMPEDE-VTE - Calculadora Médica - Vera